Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732

作者：Kim, Yoo Mee; An, Juan Ji; Jin, Yong-Jun; Rhee, Yumie; Cha, Bong Soo; Lee, Hyun Chul; Lim, Sung-Kil^*

来源：Journal of Molecular Endocrinology, 2007, 38(3-4): 455-465.

DOI：10.1677/jme.1.02165

• PROOPIOMELANOCORTIN MESSENGER-RNA
• ENDOTHELIAL-CELL APOPTOSIS
• BRAIN-BARRIER PERMEABILITY
• METHIONINE AMINOPEPTIDASE
• ANGIOGENESIS INHIBITOR
• MELANOCORTIN AGONIST
• FOOD-INTAKE
• OBESITY
• MICE
• LEPTIN

The systemic treatment with angiogenesis inhibitor has been shown to result in weight reduction and adipose tissue loss in various models of obesity. To verify the mechanism of CKD-732 (TNP-470 analog) against obesity, we evaluated CKD-732's peripheral and central anti-obesity effects. CKD-732 was injected subcutaneously (s.c.) for 7 days in various animal models and intracerebroventricularly (i.c.v.) in arcuate nucleus (ARC) lesion mice, oblob mice, and normal littermates. Modulation of the hypothalamic neuropeptide mRNAs after i.c.v. injection was evaluated in ARC lesion mice and normal littermates. A conditioned taste aversion (CTA) was performed using lithium chloride (LiCl;) as a positive control agent in Long-Evans Tokushima Otsuka and Otsuka Long-Evans Tokushima fatty (OLETF) rats. As a result, 7 days of CKD-732 s.c. injection reduced the cumulative food intake and the body weight significantly in both treated obese (e.g. 114(.)8 +/- 13(.)4 g vs 170(.)17 +/- 20(.)6 g, 7(..)9 +/- 0(.)5% decrease vs 0(.)3 +/- 2(.)2% decrease; in treated OLETF rat versus control OLETF rat, P < 0(.)01 respectively) and non-obese models. Epididymal and mesenteric fat pads, and the size of adipocytes were significantly decreased in treated rats. A single i.c.v. injection decreased food intake and body weight in ARC lesion mice and oblob mice but not in normal littermates. Unexpectedly, the hypothalamic neuropeptide mRNAs were not altered by single i.c.v. injection. CKD-732 also induced a dose-dependent CTA comparable with LiCl injection, which is a commonly used agent to produce a CTA. In conclusion, CKD-732 causes significant body weight and appetite reduction, possibly by decreasing adiposity directly and inducing central anorexia, which is partly explained by a CTA. These results should be carefully verified to assess the utility of CKD-732 as an anti-obesity drug.

• 出版日期2007-3
• 单位延边大学